慢性乙型肝炎纤维化治疗中肝纤维化指数的临床意义

Clinical significance of fibrosis index in the treatment of fibrosis of chronic hepatitis B

目的探讨肝纤维化指数在HBeAg阴性慢性乙型肝炎(CHB)患者抗肝纤维化治疗中的临床意义。方法选取30例经保肝、抗肝纤维化治疗的HBeAg阴性CHB患者,分析治疗前后肝纤维化指数、血清肝纤维化指标、门静脉主干直径宽度、脾脏厚度及肝功能变化趋势。结果与治疗前比较,疗程结束后,HBeAg阴性CHB患者肝纤维化指数、血清肝纤维化指标、脾脏厚度及肝功能均明显改善(P<0.05),而门静脉主干直径宽度与治疗前比较无显著差异(P>0.05)。结论肝纤维化指数能简便、动态、更全面地反映肝纤维化变化程度,用于评估药物疗效有临床实用价值。

Objective To investigate the clinical significance of hepatic fibrosis index from hepatitis B virus e antigen（HBeAg） negative patients with chronic hepatitis B（CHB） in the clinical treatment of liver fibrosis.Methods The changes of hepatic fibrosis index,serum liver fibrosis indicators,width of portal vein diameter,thickness of the spleen and liver function were examined and compared before and after treatment with liver-protective drugs in 30 patients diagnosed as HBeAg negative CHB.Results Compared to before,hepatic fibrosis index,serum liver fibrosis indicators,thickness of the spleen and liver function were significantly improved after treatment（P0.05）,whereas there was no significant difference in width of portal vein diameter（P0.05）.ConclusionHepatic fibrosis index can reflect the changes of liver fibrosis simply,dynamically and comprehensively,which is valuable in evaluating the efficacy of treatment.